Dual inhibition of AT1 receptor for angiotensin II and neprilysin or ACE inhibition?
Authors:
J. Špinar 1,2; L. Špinarová 3; J. Vítovec 3
Authors place of work:
Interní kardiologická klinika LF MU a FN Brno 2 Mezinárodní centrum klinického výzkumu, FN u sv. Anny v Brně 3 I. interní kardioangiologická klinika LF MU a FN u sv. Anny v Brně
1
Published in the journal:
Kardiol Rev Int Med 2018, 20(1): 47-53
Summary
Dual antagonist of AT1 receptors for angiotensin II and neprilysin, with the generic name sacubitril valsartan (formaly LCZ 696 or angiotensin receptor blocker and neprilysin inhibitor – ARNI) was clinically tested in the treatment of hypertension and heart failure. The mechanism of action is in the blockade of AT1 receptors by valsartan in combination with the inhibition of natriuretic peptides degradation, which leads to increased vasodilatation. The first clinical trial PARAMOUNT with LCZ696 in the treatment of heart failure patients with preserved ejection fraction has shown a significant decrease of NT-proBNP concentrations. Clinical trial PARADIGM-HF in patients with decreased ejection fraction and high natriuretic peptides levels was finished prematurely for a positive effect of LCZ696 as compared with enalapril. Cardiovascular mortality decreased by 20% and first hospitalisation for heart failure by 21%. The PARAGON-HF study is testing the effect of these drugs in patients with preserved ejection fraction. We show a summary of information supporting and questioning the suggestion that ARNI could replace ACE inhibitors in the treatment of heart failure.
Key words:
ACE inhibitors – sacubitril valsartan – heart failure
Zdroje
1. Špinar J, Vítovec J. Blokáda systému renin angiotenzin v léčbě kardiovaskulárních onemocnění. Interv Akut Kardiol 2010; 9(5): 252–257.
2. Málek F. Duální inhibice angiotenzinu a neprilyzinu – revoluční princip léčby chornického srdečního selhání se sníženou ejekční frakcíí levé komory. Kardiol Rev Int med 2016; 18(4): 295–298.
3. Ruilope LM, Dukat A, Bohm M et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010; 375(9722): 1255–1266. doi: 10.1016/ S0140-6736(09)61966-8.
4. Solomon SD, Zile M, Pieske B et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 doubleblind randomised controlled trial. Lancet 2012; 380(9851): 1387–1395. doi: 10.1016/ S0140-6736(12)61227-6.
5. Vítovec J, Špinar J. VALIANT – Valsartan, captopril nebo obojí u infarktu myokardu komplikovaného srdečním selháním a/ nebo dysfunkcí levé komory – samostatně ano, společně ne. Klin Farmakol Farm 2004; 18(1): 53–54.
6. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM – Overall programme. Lancet 2003; 362(9386): 759–766.
7. Pilote L, Abrahamowicz M, Eisenberg M et al. Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. CMAJ 2008; 178(10): 1303–1311. doi: 10.1503/ cmaj.060068.
8. Pilote L, Abrahamowicz M, Rodrigues E et al. Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect? Ann Intern Med 2004; 141(2): 102–112.
9. Marcus LS, Hart D, Packer M et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 1996; 94(12): 3184–3189.
10. Yoshimura M, Yasue H, Morita E et al. Hemodynamic, renal and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 1991; 84(4): 1581–1588.
11. Colucci WS, Elkayam U, Horton DP et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2000; 343(4): 246–253. doi: 10.1056/ NEJM200007273430403.
12. Ludka O. Ularitid v léčbě akutně dekompenzovaného srdečního selhání – výsledky studie TRUE-AHF. Kardiol Rev Int Med 2017; 19(3): 172–176.
13. Margulies KB, Barclay PL, Burnett JC jr. The role of neutral endopeptidase in dogs with evolving congestive heart failure. Circulation 1995; 91(7): 2036–2042.
14. Rouleau JL, Pfeffer MA, Stewart DJ et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000; 356(9230): 615–620.
15. Kostis JB, Packer M, Black HR et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004; 17(2): 103–111.
16. Packer M, Califf RM, Konstam MA et al. OVERTURE Study Group. Comparison of omapatrilat and enalapril in patients with chronic heart failure. the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002; 106(8): 920–926.
17. McMurray JJ, Packer M, Desai AS et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371(11): 993–1004. doi: 10.1056/ NEJMoa1409077.
18. Špinar J, Špinarová L, Vítovec J. Studie PARADIGM-HF možná změní léčbu srdečního selhání. Hypertenze a kardiovaskulární prevence 2014; 2: 25–26.
19. Špinarová L, Špinar J, Vítovec L. Co nám přináší studie PARADIGM-HF. Kardiol Rev Int Med 2014; 16(5): 395–397.
20. Špinarová L, Špinar J. Co zaznělo na kongresu AHA 2016 v New Orleansu. Kardiol Rev Int med 2016; 18(4): 295–298.
21. Widimský J, Lánská V, Magulová D et al. Průzkum stavu aktuální praxe diagnostiky a léčby srdečního selhání v ordinacích všeobecných lékařů v České a Slovenské republice v roce 1999. 2. část programu IMPROVEMENT of HF. Cor Vasa 2001; 43(7): 345–352.
22. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J 2016; 37(27): 2129–2200. doi: 10.1093/ eurheartj/ ehw128.
23. Špinar J, Hradec J, Špinarová L et al. Summary of the 2016 ESC Guidelines on the diagnosis and treatment of acute and chronic heart failure. Prepared by the Czech Society of Cardiology. Cor Vasa 2016; 58(5): e530–e568.
24. Špinar J, Špinarová L, Pařenica J. FAR NHL – FARmacology and NeuroHumoraL activation in chronic heart failure – the role of disease severity, neurohumoral activation and comorbidities for one year prognosis. Eur J Heart Fail 2018. In press.
Štítky
Paediatric cardiology Internal medicine Cardiac surgery CardiologyČlánok vyšiel v časopise
Cardiology Review
2018 Číslo 1
Najčítanejšie v tomto čísle
- Overview of echocardiographic parameters in the diagnostics of heart failure with preserved ejection fraction of the left ventricle
- Specifics of diagnostics and treatment in old age
- Heart failure in old age
- Old-age thyroid disease and cardiovascular disorders